Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Multitarget stool DNA tests — which are becoming more popular in the United States — have shown increased sensitivity over fecal immunochemical tests (FITs) for early colorectal cancer (CRC) screening ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

Pharmacy-based CRC screening programs using FIT can improve early detection, especially in underserved communities, with effective follow-up care. Patients prefer digital updates for negative results ...

A mailed fecal immunochemical test (FIT) outreach followed by patient navigation for those with a positive test increased colorectal cancer (CRC) screening participation at 6 months compared with ...

Please provide your email address to receive an email when new articles are posted on . Patients who received mailed outreach had a higher rate of screening completion at 6 months vs. those who ...

Adding a deadline to a mailed invitation for FIT colorectal cancer screening resulted in improved return rates. The highest return rate was seen with a 2-week deadline. This intervention can be easily ...

The analysis included 1103 people (aged 52 to 85 years) who died from colorectal adenocarcinoma between 2011 and 2017, and 9608 controls. HealthDay News — Screening with fecal immunochemical tests ...

The goal of this literature review is to provide information on both the FIT and MT-sDNA test to assist providers in advising patients on other options for colorectal cancer screening in situations ...

FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...